Sector News

GSK sells meningitis vaccines to Pfizer

June 22, 2015
Life sciences
GlaxoSmithKline will sell its meningitis vaccines Nimenrix and Mencevax to Pfizer to satisfy regulatory conditions for its asset-swap deal with Novartis.
 
The European Commission and other antitrust regulators were concerned because GSK acquired two rival meningitis vaccines – Menveo and Bexsero – from Novartis as part of the deal, which could have given the company too much power in the market.
 
Nimenrix and Mencevax are older vaccines that had combined sales of £34 million last year. The total value of the transaction with Pfizer is £82 million.
 
“Adding these two innovative and complementary vaccines to our current portfolio will allow us to more completely respond to meningococcal disease outbreaks as well as proactively address a critical public health need – the prevention of meningococcal disease across all ages,” says Susan Silbermann, president of Pfizer Vaccines.
 
“Acquiring these quadrivalent vaccines will broaden our ability to address the burden of meningococcal meningitis – an uncommon but serious and sometimes fatal disease.”
 
Last year Pfizer purchased another meningitis vaccine, Baxter’s NeisVac-C, and had its own serogroup B meningococcal disease drug Trumenba approved.
 
The sale is expected to be completed by the end of the year.
 
By George Underwood
 
Source: Pharma Times

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.